TMCI Quote, Financials, Valuation and Earnings

Accuray has a net margin of -0.73% compared to Treace Medical Concepts's net margin of 2.18%. Treace Medical Concepts's return on equity of -46.9% beat Accuray's return on equity of -9.63%.

Treace Medical Concepts has a consensus price target of $11.29, signalling upside risk potential of 58.95%. On the other hand Accuray has an analysts' consensus of $6.13 which suggests that it could grow by 300.33%. Given that Accuray has higher upside potential than Treace Medical Concepts, analysts believe Accuray is more attractive than Treace Medical Concepts.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Accuray has a beta of 1.305, suggesting its more volatile than the S&P 500 by 30.535%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Accuray pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $68.7M, which are smaller than Accuray quarterly revenues of $116.2M. Treace Medical Concepts's net income of -$501K is lower than Accuray's net income of $2.5M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Accuray's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.11x versus 0.34x for Accuray. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -0.73% compared to Treace Medical Concepts's net margin of --. Treace Medical Concepts's return on equity of -46.9% beat Perspective Therapeutics's return on equity of --.

Treace Medical Concepts has a consensus price target of $11.29, signalling upside risk potential of 58.95%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 741.69%. Given that Perspective Therapeutics has higher upside potential than Treace Medical Concepts, analysts believe Perspective Therapeutics is more attractive than Treace Medical Concepts.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $68.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Treace Medical Concepts's net income of -$501K is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.11x versus 11.07x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -0.73% compared to Treace Medical Concepts's net margin of -58.2%. Treace Medical Concepts's return on equity of -46.9% beat Masimo's return on equity of -23.05%.

Treace Medical Concepts has a consensus price target of $11.29, signalling upside risk potential of 58.95%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 34.91%. Given that Treace Medical Concepts has higher upside potential than Masimo, analysts believe Treace Medical Concepts is more attractive than Masimo.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $68.7M, which are smaller than Masimo quarterly revenues of $600.7M. Treace Medical Concepts's net income of -$501K is higher than Masimo's net income of -$349.6M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.11x versus 3.75x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -0.73% compared to Treace Medical Concepts's net margin of -10.04%. Treace Medical Concepts's return on equity of -46.9% beat Xtant Medical Holdings's return on equity of -35.34%.

Treace Medical Concepts has a consensus price target of $11.29, signalling upside risk potential of 58.95%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 358.96%. Given that Xtant Medical Holdings has higher upside potential than Treace Medical Concepts, analysts believe Xtant Medical Holdings is more attractive than Treace Medical Concepts.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $68.7M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Treace Medical Concepts's net income of -$501K is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.11x versus 0.43x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.